{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:34:30Z","timestamp":1780619670523,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005205","name":"AstraZeneca Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejca.2021.06.005","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T16:17:51Z","timestamp":1627748271000},"page":"485-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Real-world incidence of symptomatic skeletal events and bone-modifying agent\u00a0use in castration-resistant prostate cancer \u2013 an Australian multi-centre observational study"],"prefix":"10.1016","volume":"157","author":[{"given":"Angelyn","family":"Anton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5521-2284","authenticated-orcid":false,"given":"Julia","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Weickhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7350-5622","authenticated-orcid":false,"given":"Arun","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7053-680X","authenticated-orcid":false,"given":"Edmond M.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Spain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9713-1872","authenticated-orcid":false,"given":"Ashray","family":"Gunjur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Parnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-0484","authenticated-orcid":false,"given":"Jeffrey","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6091-3034","authenticated-orcid":false,"given":"Marie C.","family":"Semira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Pezaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ejca.2021.06.005_bib1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2021.06.005_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1475-097X.2010.00999.x","article-title":"Relation between pain and skeletal metastasis in patients with prostate or breast cancer","volume":"31","author":"Levren","year":"2011","journal-title":"Clin Physiol Funct Imag"},{"issue":"12","key":"10.1016\/j.ejca.2021.06.005_bib3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.5489\/cuaj.5053","article-title":"The burden of symptomatic skeletal events in castrate-resistant prostate cancer patients with bone metastases at three Canadian uro-oncology centres","volume":"12","author":"Saad","year":"2018","journal-title":"Can Urol Assoc J"},{"issue":"34_suppl","key":"10.1016\/j.ejca.2021.06.005_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.34_suppl.188","article-title":"Incidence of skeletal-related events in men with castration-resistant prostate cancer","volume":"36","author":"Kawai","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.06.005_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175956","article-title":"Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: the impact of alternative measures of radiation to the bone","volume":"12","author":"Onukwugha","year":"2017","journal-title":"PloS One"},{"issue":"19","key":"10.1016\/j.ejca.2021.06.005_bib6","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2021.06.005_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2015.09.011","article-title":"Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics","volume":"53","author":"Lipton","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.06.005_bib8","doi-asserted-by":"crossref","first-page":"vi507","DOI":"10.1093\/annonc\/mdw390.33","article-title":"Symptomatic skeletal events (SSEs) versus skeletal-related events (SREs) in patients with advanced cancer and bone metastases treated with denosumab or zoledronic acid","volume":"27","author":"von Moos","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.06.005_bib9","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann Oncol"},{"issue":"9768","key":"10.1016\/j.ejca.2021.06.005_bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2021.06.005_bib11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eururo.2013.05.015","article-title":"Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-kappaB ligand inhibitors in patients with advanced prostate cancer","volume":"65","author":"Gartrell","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ejca.2021.06.005_bib12","doi-asserted-by":"crossref","first-page":"E305","DOI":"10.1016\/j.clgc.2014.11.008","article-title":"Severe hypocalcemia associated with denosumab in metastatic castration-resistant prostate cancer: risk factors and precautions for treating physicians","volume":"13","author":"Autio","year":"2015","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2021.06.005_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/SPC.0000000000000280","article-title":"The role of bone-targeted therapies for prostate cancer in 2017","volume":"11","author":"Traboulsi","year":"2017","journal-title":"Curr Opin Support Palliat Care"},{"issue":"4","key":"10.1016\/j.ejca.2021.06.005_bib14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.ejca.2021.06.005_bib15","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.06.005_bib16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2015-0327","article-title":"The clinical and economic impacts of skeletal-related events among medicare enrollees with prostate cancer metastatic to bone","volume":"21","author":"McDougall","year":"2016","journal-title":"Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2021.06.005_bib17","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2021.06.005_bib18","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.06.005_bib19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.06.005_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.5007","article-title":"Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333\/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis","volume":"37","author":"Tombal","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.06.005_bib21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.euo.2019.02.007","article-title":"Radium-223 within the evolving treatment options for metastatic castration-resistant prostate cancer: recommendations from a European expert working group","volume":"3","author":"O'Sullivan","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"3-b Suppl","key":"10.1016\/j.ejca.2021.06.005_bib22","first-page":"S1","article-title":"Evaluation of treatment patterns and costs in patients with prostate cancer and bone metastases","volume":"25","author":"Wen","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ejca.2021.06.005_bib23","doi-asserted-by":"crossref","first-page":"100212","DOI":"10.1016\/j.jbo.2018.100212","article-title":"A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe","volume":"14","author":"Body","year":"2019","journal-title":"J Bone Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2021.06.005_bib24","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Parker","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.06.005_bib25","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ejca.2021.06.005_bib26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.ejca.2021.06.005_bib27","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1158\/1078-0432.CCR-11-2944","article-title":"Denosumab dose selection for patients with bone metastases from solid tumors","volume":"18","author":"Doshi","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2021.06.005_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ejca.2021.06.005_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.08.019","article-title":"A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"142","author":"Clemons","year":"2021","journal-title":"Eur J Cancer"},{"issue":"suppl 7S","key":"10.1016\/j.ejca.2021.06.005_bib30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.2019.37.7_suppl.139","volume":"37","author":"Silke Gillessen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7_suppl","key":"10.1016\/j.ejca.2021.06.005_bib31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.2019.37.7_suppl.139","volume":"37","author":"Gillessen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.06.005_bib32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.ejca.2021.06.005_bib33","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/1060028014539919","article-title":"Time course of calcium concentrations and risk factors for hypocalcemia in patients receiving denosumab for the treatment of bone metastases from cancer","volume":"48","author":"Ikesue","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ejca.2021.06.005_bib34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","article-title":"Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases","volume":"69","author":"Otto","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"10024","key":"10.1016\/j.ejca.2021.06.005_bib35","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2021.06.005_bib36","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.06.005_bib37","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.juro.2009.08.048","article-title":"Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer","volume":"182","author":"Smith","year":"2009","journal-title":"J Urol"},{"issue":"30","key":"10.1016\/j.ejca.2021.06.005_bib38","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.06.005_bib39","doi-asserted-by":"crossref","first-page":"1525832","DOI":"10.1155\/2018\/1525832","article-title":"The current role of osteoclast inhibitors in patients with prostate cancer","volume":"2018","author":"Kozyrakis","year":"2018","journal-title":"Adv Urol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921003695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921003695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:36:27Z","timestamp":1760733387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921003695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":39,"alternative-id":["S0959804921003695"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.06.005","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world incidence of symptomatic skeletal events and bone-modifying agent\u00a0use in castration-resistant prostate cancer \u2013 an Australian multi-centre observational study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}